Clin2
NCT06561178Possibly a fitRecruiting

Blood Test to Monitor Esophageal Cancer After Surgery

Esophageal Squamous Cell Carcinoma

Part of Cancer, Digestive system clinical trials.

This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
50 people
Ages
Any age
Study type
Observational

Who can take part

  • You have a type of esophageal cancer (squamous cell) that is locally advanced and can be surgically removed.
  • You received chemotherapy and radiation before surgery, with or without immunotherapy, and the tumor was not completely gone when the removed tissue was checked.
  • You are healthy enough to receive immunotherapy after surgery (ECOG score of 0 or 1).
  • You have stored tumor tissue and blood samples available for special DNA testing.
  • Your doctor expects you to survive at least 6 months after surgery.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04460352Recruiting· Phase 3
Esophageal cancer treatment with chemoradiation plus planned surgery

This trial tests the best way to treat locally advanced squamous cell esophageal cancer: either chemoradiation followed by planned surgery, or monitoring with surgery only if needed. It may help you choose a strategy that controls the cancer while aiming to reduce unnecessary procedures.

Montreal, Quebec
NCT07312578Enrolling by invitation· Phase 2
Targeted drugs plus chemo before surgery for esophageal cancer

This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.

Beijing, Beijing Municipality
NCT06190639Recruiting· Phase 2
Sintilimab after surgery for node-positive esophageal cancer

This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.

Hangzhou, Zhejiang
NCT07482774Not yet recruiting
Chemo-immunotherapy before surgery for esophageal cancer

This trial tests combining chemotherapy with immunotherapy before surgery for esophageal squamous cell carcinoma. It aims to see how these treatments change the tumor environment and may increase the chance of successful surgery.

NCT04174079Recruiting
Chemotherapy after esophagus surgery for lymph node spread

This trial studies whether adding chemotherapy after surgery for esophageal squamous cell cancer can reduce the chance the cancer returns. It focuses on people whose surgery removed cancerous lymph nodes and who are healthy enough to tolerate chemotherapy.

Guangzhou, Guangdong
NCT05759325Not yet recruiting
Blood test to predict response in esophagus cancer

This trial studies whether a special blood test can help predict how well treatment will work for people with stage II–IVA esophageal squamous cell carcinoma. It may help doctors identify who is more likely to benefit from therapy, based on changes seen in the blood over time.

Hear when a new Esophageal Squamous Cell Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.